Ralinepag XR is a Small Molecule owned by United Therapeutics, and is involved in 11 clinical trials, of which 7 were completed, and 4 are ongoing.
Ralinepag (APD-811) acts as PGI2 receptor agonist. The drug candidate binds to the prostacyclin receptor (IP) located on the surface of platelets and vascular smooth muscle cells. The IP receptor is a G-protein coupled receptor that upon activation by drug candidate, stimulates the formation of cyclic adenosine monophosphate (cAMP). Prostacyclin counteracts the vasoconstrictor and pro-thrombotic activity of endothelin. The drug candidate by agonizing PGI2 receptor regulates vascular smooth muscle tone and thereby slows disease progression and improves exercise tolerance in PAH patients.
The revenue for Ralinepag XR is expected to reach a total of $620m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ralinepag XR NPV Report.
Ralinepag XR Overview
Ralinepag (APD-811) is under development for the treatment of pulmonary arterial hypertension (PAH). It is a next-generation drug that is administered through oral route. It acts by targeting PGI2 receptor. It is developed based on GPCR-based drug discovery technology.
Everest Medicines Overview
Everest Medicines, is a biopharmaceutical company that licenses, develops and commercializes medicines for the treatment of cancer, autoimmune, cardio renal and infectious diseases. It is investigating Sacituzumab govitecan, an antibody-drug conjugate targeting metastatic triple-negative breast cancer (mTNBC), metastatic urothelial cancer (mUc), non-small cell lung cancer (NSCLC) and other oncology indications; and FGF401 for hepatocellular carcinoma. The company is evaluating Etrasimod to treat ulcerative colitis and other autoimmune diseases; Nefecon for IgA nephropathy; Ralinepag against pulmonary arterial hypertension (PAH). Everest Medicines is also developing drugs for community-acquired bacterial pneumonia (CABP), complicated urinary tract infection (cUTi) and other infectious diseases. It works in partnership with Immunomedics, Novartis, Arena Pharmaceuticals and other companies to develop its products. Everest Medicines is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY0.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was CNY1,026.3 million in FY2021, compared to an operating loss of CNY688.5 million in FY2020. The net loss of the company was CNY1,008.7 million in FY2021, compared to a net loss of CNY5,658.2 million in FY2020.
Quick View – Ralinepag XR
|Highest Development Stage|